Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/7744486 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 07.06.2026. Verfasst von Pedro-Antonio Regidor und 3 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This trial was conducted to investigate the bleeding pattern, tolerability, and safety of the low‐dose prolonged‐release combined oral contraceptive (COC) containing dienogest (DNG) and ethinylestradiol (EE) in three different dosages for an extended regimen. This extended regime is expected to reduce menses‐related symptoms like headaches, breast disorders, menorrhagia, or dysmenorrhea. The dosages were compared to an immediate‐release COC containing 0.02‐mg EE and 3‐mg drospirenone in a flexible, long‐cycle regime. Materials and Methods Multicenter, open‐label, active‐controlled trial in four parallel groups of female patients aged 18–35. Three different doses of test products containing 1‐mg DNG/0.01‐mg EE, 2‐mg DNG/0.01‐mg EE, and 2‐mg DNG/0.02‐mg EE versus the reference product were investigated in two 91‐day treatment periods. Each treatment period included 87 days of active treatment, followed by a tablet‐free interval of 4 days. The product containing 2‐mg DNG/0.02‐mg EE was the only one of the prolonged‐release formulations granted market authorization for contraception.
Results
The mean (SD) number of scheduled bleeding/spotting days decreased from 7.4 (2.29) during treatment period 1 to 2.4 (2.28) during treatment period 2 for the 2‐mg DNG/0.02‐mg EE group compared to 6.6 (2.20) days during treatment period 1 and 2.7 (2.45) days during treatment period 2 for the comparator. The mean (SD) number of unscheduled bleeding/spotting days decreased from 18.3 (18.60) during treatment period 1 to 9.7 (13.60) during treatment period 2 for the 2‐mg DNG/0.02‐mg EE group, in contrast to 23.8 (21.37) days during treatment period 1 and 11.5 (14.58) days during treatment period 2 for the comparator. The general satisfaction was 87.5% for the 2‐mg DNG/0.02‐mg EE patient group. The absence rate of any bleeding days increased from 70.7% during treatment period 1 to 86.5% during treatment period 2 for the 2‐mg DNG/0.02‐mg EE group compared to 65.9% and 84.2%, respectively, for the comparator.
Conclusions
The prolonged‐release COC with 2‐mg DNG/0.02‐mg EE offers a solid alternative for extended use, with a high rate of no bleeding days and a high satisfaction rate among users. Trial Registration: EudraCT number: 2016‐003831‐39
Zitieren
APA
Regidor, P., Angulo, A., Munoz, A., & Colli, E. (2026). Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/7744486
Vancouver
Regidor P, Angulo A, Munoz A, Colli E. Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/7744486
BibTeX
@article{Regidor2026,
author = {Regidor, Pedro-Antonio and Angulo, Alicyoy and Munoz, Alejandro and Colli, Enrico},
title = {Safety and Tolerability of Three Different Prolonged‐Release Dienogest/Ethinylestradiol Contraceptive Pills in an Extended 181‐Day Treatment Regimen Compared to a Flexible Immediate‐Release Formulation With Drospirenone/Ethinylestradiol},
journal = {International Journal of Clinical Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijcp/7744486}
}
EUVIMED